All News

guidelines.recommendations.jpg

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

Jack Cush, MD

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article
hidradenitis.jpg

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Jack Cush, MD

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.

Read Article
heel enthesitis spur calcaneal

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

Jack Cush, MD

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article
Psoriasis Severe legs sara

Difficult-to-Treat Psoriasis

Jack Cush, MD

This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.

Read Article
mtx.png (keep)

No Risk of Interstitial Lung Disease with Methotrexate Use

Jack Cush, MD

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA) https://t.co/JjhkQM672t. https://t.co/dM25kIcC26

Links:

Dr. John Cush RheumNow ( View Tweet)
Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G

Links:

Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/y3UvOF4M5i https://t.co/iSUrkhIXbh

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/BHnTciKU1f https://t.co/P7gDZUSGRw

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-Treat Psoriasis This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics. https://t.co/OWzmYShqBs https://t.co/u1995MAB15

Links:

Dr. John Cush RheumNow ( View Tweet)
RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150

Dr. John Cush RheumNow ( View Tweet)

Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. https://t.co/xA8YYCi94r https://t.co/RyS6vnlzam

Links:

Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×